Innate Pharma (XPAR:IPH) Long-Term Debt : €30.61 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Long-Term Debt?

Innate Pharma's Long-Term Debt for the quarter that ended in Dec. 2023 was €30.61 Mil.

Innate Pharma's quarterly Long-Term Debt declined from Dec. 2022 (€38.93 Mil) to Jun. 2023 (€0.00 Mil) but then increased from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€30.61 Mil).

Innate Pharma's annual Long-Term Debt increased from Dec. 2021 (€11.49 Mil) to Dec. 2022 (€38.93 Mil) but then declined from Dec. 2022 (€38.93 Mil) to Dec. 2023 (€30.61 Mil).

Innate Pharma Long-Term Debt Historical Data

The historical data trend for Innate Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Long-Term Debt Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

14.10

14.19

11.49

38.93

30.61

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															11.49	12.52	38.93	-	30.61

Innate Pharma (XPAR:IPH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Innate Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines